摘要
目的探讨重组人脑利钠肽(rhBNP)序贯治疗联合沙库巴曲缬沙坦钠片对急性心力衰竭(AHF)患者临床疗效的影响。方法回顾性选取周口市中心医院2022年1月至2023年12月收治的AHF患者80例,根据不同治疗方案分为对照组和观察组,每组40例。对照组采用沙库巴曲缬沙坦钠片治疗;观察组在rhBNP序贯治疗基础上加用沙库巴曲缬沙坦钠片。两组均治疗2个月后判定疗效。对比两组左室射血分数(LVEF)、左心室收缩末内径(LVESD)、左心室舒张末内径(LVEDD)、每搏输出量(SV)、内皮素-1(ET-1)、氨基末端脑钠肽前体(NT-proBNP)、醛固酮(ALD)、血管紧张素Ⅱ(AngⅡ)、去甲肾上腺素(NA)及不良反应。结果观察组有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组LVEF、SV均升高,且观察组高于对照组,差异有统计学意义(P<0.05);两组LVESD、LVEDD均降低,且观察组低于对照组,差异有统计学意义(P<0.05);两组ET-1、NT-proBNP、ALD、AngⅡ、NA水平均降低,且观察组低于对照组,差异有统计学意义(P<0.05)。两组不良反应对比,差异无统计学意义(P>0.05)。结论rhBNP序贯治疗联合沙库巴曲缬沙坦钠片可改善AHF患者的心功能,降低神经内分泌激素水平,提高临床疗效,且安全性良好。
Objective To investigate the effect of recombinant human brain natriuretic peptide(rhBNP)sequential therapy combined with sacubitril/valsartan sodium tablets on the clinical efficacy in patients with acute heart failure(AHF).Methods A total of 80 AHF patients admitted to Zhoukou Central Hospital from January 2022 to December 2023 were selected and divided into a control group and an observation group according to different treatment regimens,with 40 cases in each group.The control group was treated with sacubitril/valsartan sodium tablets,while the observation group was treated with sacubitril/valsartan sodium tablets on the basis of rhBNP sequential therapy.Clinical efficacy was evaluated after 2 months of treatment in both groups.Left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVESD),left ventricular enddiastolic diameter(LVEDD),stroke volume(SV),endothelin-1(ET-1),N-terminal pro-brain natriuretic peptide(NT-proBNP),aldosterone(ALD),angiotensinⅡ(AngⅡ),noradrenaline(NA)and adverse reactions were compared between the two groups.Results The total effective rate in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).After treatment,LVEF and SV in both groups increased,and those in the observation group were higher than in the control group,with statistically significant differences(P<0.05).LVESD and LVEDD in both groups decreased,and those in the observation group were lower than in the control group,with statistically significant differences(P<0.05).The levels of ET-1,NT-proBNP,ALD,AngⅡand NA in both groups decreased,and those in the observation group were lower than in the control group,with statistically significant differences(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion rhBNP sequential therapy combined with sacubitril/valsartan sodium tablets can improve cardiac function,reduce neuroendocrine hormone levels,and enhance clinical efficacy in patients with AHF,with good safety.
作者
左艳芳
吴广留
郭坤
刘诫
高振
ZUO Yanfang;WU Guangliu;GUO Kun;LIU Jie;GAO Zhen(Cardiovascular Surgery Intensive Care Unit,Zhoukou Central Hospital,Zhoukou Henan 466000 China;Division of Cardiovascular Surgery,Zhoukou Central Hospital,Zhoukou Henan 466000 China)
出处
《临床研究》
2025年第12期48-51,共4页
Clinical Research
关键词
急性心力衰竭
重组人脑利钠肽
序贯治疗
沙库巴曲缬沙坦钠片
心功能
内皮素-1
氨基末端脑钠肽前体
acute heart failure
recombinant human brain natriuretic peptide
sequential therapy
sacubitril/valsartan sodium
cardiac function
endothelin-1
N-terminal pro-brain natriuretic peptide
